0
Interim Results PresentationFor the six months ended 31 October 2011Presented by:Andrew Newland, Chief Executive OfficerIa...
Legal disclaimerThe information and opinions contained in this presentation are provided as at the date hereof and are sub...
Operational HighlightsParsortix Cancer Diagnostics•   Holding increased to 90%•   Technology successfully used to capture ...
Financial Results for the six months ended 31 October 2011CONTINUING OPERATIONS                           H1 2012   H1 201...
Update on Novocellus: IVF embryo viabilityAs announced today•   Novocellus has a partnership with ORIGIO, a leading suppli...
Parsortix: cancer diagnostics separation cassette schematic                                   Cassette components         ...
Captured cells: whole blood control and spiked with SK-Br-3ControlSpiked withbreast cancercells                           ...
Chromogenic staining of SK-Br-3 cellsStained breastCancer cellsVisual IDbreast cancercells                          Identi...
Parsortix UpdateAnnounced this week•   Achieved major milestone by using Parsortix cell separation device to successfully ...
Key Milestones for Parsortix for 2012• Finalise work on characterising the separation device including flow and  volume ca...
Investment Summary• ANGLE’s three major investments offer potential for substantial returns• Parsortix and Novocellus targ...
Contact details Andrew Newland Chief Executive ANGLE plc 3 Frederick Sanger Road The Surrey Research Park Guildford GU2 7Y...
Upcoming SlideShare
Loading in...5
×

Angle interim results 2012 26jan12

206

Published on

Interim Results Presentation for the six months ended 31 October 2011

Published in: Business, Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
206
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Angle interim results 2012 26jan12"

  1. 1. Interim Results PresentationFor the six months ended 31 October 2011Presented by:Andrew Newland, Chief Executive OfficerIan Griffiths, Finance Director26 January 2012
  2. 2. Legal disclaimerThe information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (withoutnotice), verification and completeness.This document is directed at investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (FinancialPromotion) Order 2005 and at organisations of a kind described in and to whom Article 49 of the Financial Services and Markets Act 2000(Financial Promotion) Order 2005 (High Net Worth Companies, Unincorporated Associations, etc.) applies (all such persons together beingreferred to as "relevant persons"). This document must not be acted on, or relied on by, or passed on to (directly or indirectly) personswho are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant personsand will be engaged in only with relevant persons (save as set out below). This document is confidential and is being supplied to you solely for your information and may not be reproduced, redistributed or passedon, directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided torecipients on the basis that they keep confidential any information contained herein or otherwise made available, whether orally or inwriting, in connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or takeninto the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it bedistributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States SecuritiesAct of 1933, (as amended) (the “US Securities Act”)). This document does not constitute an offer to buy or to subscribe for, or thesolicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or used in jurisdictionsoutside the UK, any such recipient or user should inform themselves about and observe any applicable legal requirements. Neither thisdocument nor any part of this document should be copied or distributed by recipients and, in particular, should not be distributed by anymeans, including electronic transmission, to persons with addresses in the United States of America (or any of its territories orpossessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationalsthereof, or to any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside theUnited Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution could result inviolation of the laws of such countries.This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase anysecurities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose whatsoever onthe information, representation or opinions.This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers,agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of theCompany after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projectionsor opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipientshould satisfy itself in relation to such matters. Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the accuracy,completeness or fairness of the information and opinions contained in this document, nor does the Company accept any responsibility orliability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connectiontherewith. © ANGLE plc 2012 Page 2
  3. 3. Operational HighlightsParsortix Cancer Diagnostics• Holding increased to 90%• Technology successfully used to capture cultured cancer cells added to healthy blood (spiked blood) and product development programme initiated for a cancer diagnostic device• Successfully captured cultured breast, prostate and lung cancer cells in spiked blood• Potential for a simple, effective and affordable technique, irrespective of cancer type, for early detection of cancer, monitoring of cancer patients during and post treatment• Granted US patent and patents are pending in all major economic territories worldwide• First research partnership, with the University of Surrey’s Oncology DepartmentOther key portfolio companiesGeomerics (33%) (computer games middleware and computer graphics)• Enlighten technology is now employed in 20 titles worldwide and in evaluation for many more• Sales secured in Korea and Japan and is an integrated partner for Epic Games’ Unreal Engine 3• Wide acclaim for the major titles, Battlefield 3 and Need for Speed: The Run, recently been released using EnlightenNovocellus (92%) (IVF embryo viability)• Novocellus’ product EmbryoSure® offers the potential for increased pregnancy rates in IVF• New terms with ORIGIO to accelerate the progress of the EmbryoSure® product to market © ANGLE plc 2012
  4. 4. Financial Results for the six months ended 31 October 2011CONTINUING OPERATIONS H1 2012 H1 2011Statement of comprehensive income £’000 £’000 CommentsTurnover 703 1,363Investments portfolio (loss) / gain (1,346) 175 Planned increase in spend on controlled investments, primarily ParsortixManagement services (623) (1,118) Impairment of £1.3m to Acolyte fair valueVentures operating costs (144) (220) Management services business smaller butOther operating costs (83) 1 still profitable and contributing to overheadProfit / (loss) before controlled investments (1,493) 201 Cash balances increased to £1.1m fromControlled investments opex (340) £0.6m (142)Profit before tax (1,833) 59 Portfolio value excludes controlled investments NeuroTargets, Novocellus andManagement services ParsortixTurnover 663 1,341 Fundraising completed during the half yearOperating costs (623) (1,118) of £1.25 millionProfit 40 223 Further successful fundraising of £1.2Statement of Financial Position 31Oct11 30Apr11 million announced todayInvestments 2,515 3,861 Funds raised to be used principally toTrade and other receivables 399 323 support ongoing development of ParsortixCash 1,093 619 and revitalised Novocellus agreement 8 with ORIGIOProperty, plant and equipment 9Intangible assets 444 443Total assets 4.459 5,254 © ANGLE plc 2012 Page 4
  5. 5. Update on Novocellus: IVF embryo viabilityAs announced today• Novocellus has a partnership with ORIGIO, a leading supplier of specialised IVF products• New improved development terms agreed between Novocellus and ORIGIO to kick start trials and accelerate timescales• ANGLE will contribute to certain costs and risk-share with ORIGIO up to £0.5 million• ANGLE’s holding in Novocellus increased to 92%• Trials with Novocellus’ product EmbryoSure® for embryo viability to commence shortly• ORIGIO targeted to launch EmbryoSure® by mid-year 2014• Financial terms to ANGLE for EmbryoSure® − Milestone payments of up to £4.5m and royalty payments of up to 25% of next sales unchanged − Royalty payments extended for additional 12 months beyond life of patents © ANGLE plc 2012 Page 5
  6. 6. Parsortix: cancer diagnostics separation cassette schematic Cassette components Fully assembled cassette Cassette housing © ANGLE plc 2012 Page 6
  7. 7. Captured cells: whole blood control and spiked with SK-Br-3ControlSpiked withbreast cancercells © ANGLE plc 2012 Page 7
  8. 8. Chromogenic staining of SK-Br-3 cellsStained breastCancer cellsVisual IDbreast cancercells Identified cells marked using cytokeratin-18 © ANGLE plc 2012
  9. 9. Parsortix UpdateAnnounced this week• Achieved major milestone by using Parsortix cell separation device to successfully capture CTCs in cancer patient blood• This is significant as actual cancer patient blood would be expected to contain only a very small number of CTCs in the sample as well as potential issues due to patient disease factors adversely affecting the performance of the separation technology• The Parsortix separation technology offers the potential for a CTC isolation, capture and characterisation device, irrespective of cancer type, for: - Early detection of cancer - Monitoring of cancer patients during treatment - Post-treatment monitoring of cancer patients in remission• Key possibility to use the captured CTCs for molecular profiling to help define tumour biology and risk of progression © ANGLE plc 2012 Page 9
  10. 10. Key Milestones for Parsortix for 2012• Finalise work on characterising the separation device including flow and volume capability• Finalise market requirements for device• Optimise design of separation device (next generation)• Establish further collaborations with cancer research centres• Beta test next generation separation device• Final design of separation device• Manufacture in quantity• Initiate sales for research purposes © ANGLE plc 2012
  11. 11. Investment Summary• ANGLE’s three major investments offer potential for substantial returns• Parsortix and Novocellus targeting highly attractive markets• Geomerics providing near term revenue generation• Diversification = risk protection• Further value enhancing milestones to be achieved over the next six to twelve months © ANGLE plc 2012
  12. 12. Contact details Andrew Newland Chief Executive ANGLE plc 3 Frederick Sanger Road The Surrey Research Park Guildford GU2 7YD United Kingdom Tel: +44 1483 685830 Fax: +44 1483 685836 Email: andrew.newland@ANGLEplc.com Website: www.ANGLEplc.com © ANGLE plc 2012 Page 12
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×